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Abstract 
Human papillomavirus (HPV) is recognized as the most prevalent sexually transmitted 
infection in the United States. Prevention of HPV infection is possible with the efficacy 
of HPV vaccine noted to be nearly 100% when introduced prior to sexual debut. In 
addition, vaccination post-sexual initiation could have a significant impact on reducing 
HPV infection and HPV-associated cancers in women. Much focus has been placed on 
vaccinating adolescents against HPV. However, strategies to increase vaccination rates 
among females ages 18-26, who remain eligible for vaccination, must be examined. A 
program evaluation was undertaken to assess the effectiveness of a newly developed pilot 
program for women ages 19-26 that incorporates assessment of vaccine eligibility during 
the prenatal period to increase uptake and completion of HPV vaccine postpartum. Data 
collected from the perinatal vaccination pilot program was performed retrospectively. 
Through a chart review, postpartum patients age 19-26 were identified and specific areas 
of focus were examined: whether an HPV dose was administered to vaccine eligible 
individuals during the inpatient period; whether an additional dose was administered at an 
ambulatory postpartum visit; and whether a subsequent dose was given at an ambulatory 
visit if warranted. Data analysis was conducted. Frequencies and percentages in relation 
to numbers of patients and HPV doses were calculated. Finally, implications for 
advanced nursing practice were discussed. 
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Evaluation of a Perinatal Human Papillomavirus Vaccination Program 
Background/Statement of the Problem 
Human papillomavirus (HPV) is recognized as the most prevalent sexually 
transmitted infection in the United States, accounting for 39,000 cases of HPV-related 
cancers including those of the cervix, vulva, vagina, penis, oropharynx, and anus 
(Petrosky et al., 2015; Saraiya et al., 2015; Centers for Disease Control, 2017). 
Approximately 100 identified strains of HPV have been identified including 40 high-risk, 
oncogenic strains (CDC, 2017).  HPV is classified as oncogenic and non-oncogenic with 
the highest incidence of cancers resulting from strains 16 and 18 (CDC, 2017).  HPV also 
accounts for the majority of cases of cervical dysplasia, a pre-cancerous condition of 
cervix. Cervical dysplasia has both a global financial impact as well as a significant 
impact on quality of life for those affected (Handler, Handler, Majewski, & Schwartz, 
2015; Petrosky et al., 2015). Notably, though not cancer causing, non-oncogenic strains 
of HPV have a significant disease burden as evidenced by the incidence of genital 
condyloma. 
Quadrivalent-HPV vaccine (4vHPV) was introduced in 2006 as the first Federal 
Drug Administration (FDA) approved vaccine, Gardasil, targeting HPV strains 16, 18, 6, 
and 11, followed by the 2009 FDA approved bivalent-HPV vaccine (2vHPV), Cervarix, 
for strains 16 and 18, and the 2015 introduction of nonavalent HPV vaccine (9vHPV), 
Gardasil9, which included the 4vHPV strains and strains 31, 33, 45, 52, and 58, an 
additional five oncogenic-associated strains (Handler et al., 2015; Petrosky et al., 2015). 
Initial recommendations by the Advisory Committee on Immunization Practices (ACIP) 
focused on vaccinating females ages 11-26 for 4vHPV and 2vHPV with 
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recommendations now in place for males ages 11-26 to receive 4vHPV (Petrosky et al., 
2015). Additionally, 9vHPV can be administered as early as age 9, to all females ages 11-
26 and males age 11-21, and up to age 26 for men who have sex with men or men who 
have sex with women and men (Petrosky et al., 2015).   
The efficacy of 4vHPV and 9vHPV in preventing strains 16, 18, 6, and 11 has 
been noted to be nearly 100% when introduced prior to sexual debut with clinical trials 
showing a nearly 97% reduction in disease associated with HPV strains 31, 33, 45, 52, 
and 58% reduction for those participants who received 9vHPV versus 4vHPV vaccine 
(Joura et al., 2015). Introduction of HPV vaccination prior to initiation of sexual activity 
is ideal. However, especially with 9vHPV, which provides vaccine coverage for an 
additional five HPV strains that are associated with 18.5% of cervical cancers, the 
introduction of this vaccine series post-sexual initiation could still have a significant 
impact on reducing HPV-associated cancers in women (Serrano et al, 2012). Vaccination 
post-sexual initiation is beneficial as it offers protection against strains that may have not 
been previously acquired (Serrano et al., 2012).  
 Despite evidence to support high levels of efficacy in preventing HPV-associated 
dysplasia and cancers with HPV vaccination, the rates of vaccination in the United States 
for adolescents ages 13-17 remain low with only 63% of females and 50% of males 
having received at least one dose of HPV vaccine (Reagan-Steiner et al., 2016). The 
evidence identifies a gap in which there is opportunity to initiate or continue the HPV 
series for those ages 18-26 (Reagan-Steiner et al., 2016).  
The female population, whose risk of disease burden is greatly impacted by HPV, 
is of significant priority. With one in four Americans at-risk for developing HPV 
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infection and 90% of cervical cancers attributed to HPV, prevention of HPV infection 
must be emphasized (Serrano et al., 2012; CDC, 2017). The United Nations’ focus on 
improving the health of the population through the Sustainable Development Goals 
(SDG) recognizes the impact that women’s health has on society. Prevention of HPV-
associated morbidity and mortality in the female population supports the prospect of a 
healthier community. Goals three through five of the SDGs apply to HPV prevention. 
The United Nations (2015) identifies these women’s health SDG goals as: 
 Goal 3. Ensure healthy lives and promote well-being for all at all ages; Goal 4. 
 Ensure inclusive and equitable quality education and promote lifelong 
 learning opportunities for all; and Goal 5. Achieve gender equality and empower 
 all women and girls (p. 18-20).  
In developing countries, HPV vaccination rates have yet to reach the same levels as 
higher income countries (World Health Organization, 2016). However, with the SDGs, 
through health promotion, education, and empowerment, the opportunity to reduce HPV 
infection or even eradicate cervical cancer for future generations,’ remains a possibility.  
HPV vaccination rates in the United States remain sub-optimal with only 34.9% 
of all adolescents ages 13-17 having received the complete three-dose series of HPV 
vaccine (Reagan-Steiner et al., 2016). In a review of the data from the National 
Immunization Survey-Teen between 2008 to 2013, HPV vaccination initiation and series 
completion among various racial and ethnic groups was examined (Burdette, Webb, Hill, 
& Jokinen-Gordon, 2017). Findings show that by 2013, initiation of the vaccine series 
increased for all racial and ethnic groups with higher rates of initiation by African-
American and Hispanic women as compared to non-Hispanic white women (Burdette et 
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al., 2017). Additionally, the likelihood of HPV vaccine series completion was greatest 
among Hispanic females as compared to non-Hispanic white females (Burdette et al., 
2017). Provider recommendation to vaccinate also showed an increase among all racial 
and ethnic groups, with a 19% increase yearly (Burdette et al., 2017). However, the 
likelihood of receiving a recommendation to vaccinate was higher among African-
American and Hispanic females (Burdette et al., 2017).  
Healthy People 2020 data indicates that HPV vaccination rate disparities continue 
to exist for those ages 13-15 among ethnic groups and household income levels (U. S. 
Department of Health and Human Service, 2017).  From 2012 to 2015, data demonstrate 
that a decrease has occured in adolescent females ages 13-15 years who identify as white-
only in receiving three doses of the HPV series (U.S. DHHS, 2017). Additionally, 
females ages 13-15 years whose mothers have a four-year college degree and a household 
income level at or above the poverty level are less likely to receive HPV vaccination 
(U.S. DHHS, 2017). Hispanic and black females, those whose mothers have less than a 
high school education, and those who live below the federal poverty level have greater 
levels of three dose HPV series completion (U.S. DHHS, 2017).  
Though much research has emphasized vaccination programs for adolescents, less 
focus has been placed on older-adolescents and young adults who are at-risk for HPV 
infection and remain eligible for vaccination. In 2012, the overall HPV vaccination rate 
through three doses of the series for girls age 13-15 was only 28.1 percent (U. S. DHHS, 
2017). This cohort of the older adolescent and young-adult subset, now ages 18-20, are at 
great risk for HPV infection due to low rates of vaccine acceptance as younger-
adolescents. In response, Healthy People 2020 has identified the need to address this risk 
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by including the developmental objective of reducing the overall proportion of females 
with HPV infection (U.S. DHHS, 2017).  Few studies have looked at whether primary 
prevention strategies result in an increase in HPV vaccination rates in this population of 
females ages 18-26. 
Strategies to increase vaccination rates among females ages 18-26 must be 
examined. With increased age, the likelihood of sexual activity and childbearing 
increases among this population. Pregnancy is a period when health promotion and 
access to health care becomes of significant importance. In Rhode Island, a Medicaid 
expansion state, uninsured pregnant women qualify for Medicaid if they are within 253% 
of the federal poverty level (Rhode Island Health & Human Services, 2017). While HPV 
vaccination is currently not recommended during pregnancy, assessment of HPV 
vaccination status should be included during prenatal care. Protocols for vaccinating 
women in the postpartum period should be explored. Educating women prenatally about 
HPV virus and their vaccine eligibility in the immediate postpartum period are of equal 
importance as individual health promotion activities may become displaced by a 
woman’s focus on infant care once hospital discharge has occurred. The implementation 
of a perinatal program that includes postpartum vaccination may increase the overall 
vaccination rates for women ages 19-26 and needs to be further explored.  
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Literature Review 
The purpose of this literature review was to identify common themes pertaining to 
human papilloma virus, HPV vaccination, and postpartum HPV vaccination. A search 
was conducted using CINAHL Plus with full text, PubMed Central, and Google. Search 
terms included human papilloma virus, HPV, vaccine, incidence, prevalence, efficacy, 
immunogenicity, rates, female, and postpartum. The reference lists of identified articles 
were reviewed for additional sources. The publication dates were limited to the time 
frame from 2006 through 2018.  
HPV Incidence and Prevalence 
 Globally, HPV is a predominant health problem with the World Health 
Organization (WHO) estimating 528,000 new cases of HPV in 2012 (WHO, 2017). 
Though many who seroconvert to an HPV-positive status have a transient viral infection, 
many others have persistent virus that can result in dysplasia or oncogenic forms of the 
disease (Braaten & Laufer, 2008). In the United States, HPV is the most prevalent 
sexually transmitted infection with an estimated 25% of the population having HPV 
infection during their lifetime (CDC, 2017). 
CDC (2017) cancer registry data attributes 39,844 cancers to HPV which 
dramatically demonstrates the magnitude of the impact that HPV has on U.S. society. 
However, the global impact of HPV incidence and prevalence must be reviewed to 
understand the effect on the world’s population. Universally, the body of literature 
regarding HPV identifies HPV as the causative agent in greater than 90% of cervical 
cancers with HPV strains 16 and 18 identified in greater than 70% of those cases 
(Serrano et al., 2012; Saraiya et al., 2015; CDC, 2017).  
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In the review of the literature by Serrano et al. (2012), the researchers examined 
two international studies to determine the relative correlation (RC) of HPV-types 
included in the 9vHPV vaccine to overall invasive cervical carcinoma rates and pre-
cancerous cervical lesions. The researchers examined a retrospective cross-sectional 
study of 10,575 invasive cervical cancer cases between 1949 and 2009 from 38 countries 
with 8,977 HPV-positive cases (de Sanjose et al., 2010; Serrano et al., 2012). Archived 
pathological samples were analyzed to determine the prevalence of each HPV-type 
attributed to cervical cancer cases in subjects classified by 10 geographical regions and 
by age-group (de Sanjose et al., 2010; Serrano et al., 2012). Additionally, data from an 
International Agency for Research on Cancer meta-analysis was reviewed to examine the 
distribution of HPV types among 115,789 HPV-positive women from 423 studies 
(Serrano et al., 2012). The researchers concluded that 89.4% of invasive cervical cancers 
had an RC to one of the 9 HPV-types included in the 9vHPV vaccine (Serrano et al., 
2012). Additionally, the RC of the 9 HPV-types to pre-cancerous diagnosis of squamous 
cell carcinoma was 89.1% and 95.5% for adenocarcinoma (Serrano et al., 2012). Using 
calculated data for 2012 and projected data for 2025 based upon global population 
growth and current HPV rates, de Sanjose et al. (2010) suggest, that without HPV 
vaccination, global cases of invasive cervical cancer could rise to greater than 627,000 
new cases in 2025. Serrano et al. (2012) theorize that greater access to 9vHPV vaccine, 
especially in developing regions of the world where cervical cancer screening programs 
are inconsistent or non-existent, could have a greater proportional impact by reducing 
HPV rates through immunity, therefore reducing overall invasive cancer rates and HPV-
related deaths.  
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In the US population, HPV presents a significant threat in terms of morbidity and 
mortality. In the research by Saraiya et al. (2015), CDC Cancer Registry Sentinel 
Surveillance System data was analyzed to determine the prevalence and types of HPV-
associated cancers in the U.S. pre-HPV vaccine implementation. Though the clinical 
correlation between HPV and cervical cancer is widely accepted, the researchers 
expanded their focus to examine additional types of HPV-associated cancers including 
those of the anus, vagina, oropharynx, vulva, penis, oral cavity, and larynx (Saraiya et al, 
2015). CDC cancer registry data was examined from 1993 to 2005 with 2,670 tissue 
samples representative of seven areas of the country that have high-rates of cervical 
cancer compared to other areas of the U.S. (Saraiya et al., 2015). The researchers 
concluded that HPV presence was highest in cases of cervical cancer in-situ (98.8%), 
cervical (90.6%), anal (91.1%), penile (63.3%), and oropharyngeal cancers (70.1%) 
(Saraiya et al., 2015). The presence of HPV-16 was highest in all types of HPV-
associated cancers (Saraiya et al., 2015). Based upon these conclusions, the researchers 
hypothesize that if the U.S. population was fully vaccinated against HPV, greater than 
24,000 HPV-associated cancers could be prevented yearly (Saraiya et al., 2015).  
HPV Vaccination Efficacy and Immunogenicity 
 The impact of HPV upon global society and the U.S. population is notable. With 
over a decade of HPV vaccination programs using 4vHPV and bivalent-HPV vaccine, 
efficacy and immune response has been well established (Joura et al., 2015). The overall 
effectiveness and immune response to 9vHPV vaccine clearly demonstrates the short-
term benefit of vaccination programs. With the introduction of 4vHPV vaccination in 
2006, ACIP adopted recommendations for routine HPV vaccinations for specific patient 
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populations (Petrosky et al., 2015). With the introduction of 9vHPV vaccine, evolving 
research on vaccine efficacy and immunogenicity has emerged. In response to this 
research, both ACIP in the U.S. and the Global Alliance for Vaccines and Immunization 
(GAVI) have expanded vaccine coverage for both the male and female populations in the 
U.S. and in developing regions of the world where it is estimated that by 2020 forty-
million girls could be protected against cervical cancer by receiving HPV vaccination 
(Petrosky et al., 2015; GAVI, 2017). 
 In clinical trials of the 9vHPV vaccine, researchers conducted a randomized, 
international, double-blind study consisting of 14,215 participants ages 16-26 randomly 
assigned to receive either 4vHPV, Gardasil, or 9vHPV, Gardasil 9, vaccine (Joura et al., 
2015). Participants were followed to observe if HPV vaccination offered risk reduction in 
developing disease related to HPV in either vaccine type (Joura et al., 2015). Results 
showed that Gardasil 9 was 96.7% effective in reducing cases of cervical, vulvar, and 
vaginal disease or cancer attributable to HPV types 31, 33, 45, 52, and 58 and that 
clinical effectiveness was comparable to 4vHPV in reducing HPV 16 and 18 (Joura et al., 
2015). Immunogenicity was also examined and showed that within the control group 
nearly 100% of participants seroconverted to the 9vHPV vaccine types and that 
geometric mean titers showed immune responses for HPV-6, 11, 16, 18 to be comparable 
to quadrivalent vaccine (Joura et al., 2015). The results of this efficacy and 
immunogenicity study showing that the 9vHPV vaccine is non-inferior to quadrivalent 
vaccine has led to the 9vHPV vaccine being accepted as the standard HPV vaccine 
option. 
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 With the 9vHPV introduction in 2015, further studies have resulted in continued 
revision of dosing schedules based upon immunogenicity. In December 2016, ACIP 
modified its 9vHPV dosing recommendations based upon clinical trials that examined the 
immune response to a 2-dose vaccine schedule for those ages 9-14 as compared to the 
traditional 3-dose regimen in those ages 16-26. Study participants consisted of 1,518 boys 
and girls from 15 countries divided into five cohorts to examine the immune response of 
varying dosing schedules as compared to the control group (Iverson et al., 2016). The 
results showed that the geometric mean titer at four weeks post vaccination for the two-
dose schedule, given at day one and month six, were non-inferior to the geometric mean 
titers for traditional three-dose vaccination (Iverson et al., 2016).  
 Prior to the aforementioned clinical trial, researchers had examined the 
immunogenicity and efficacy of receiving one, two, or three doses of the 4vHPV vaccine. 
In a prospective cohort study of 17,729 girls’ similar findings were noted in that 
participants who received two-doses at day one and month six had non-inferior geometric 
mean titers as compared to the three-dose cohort (Sankaranarayanan et al., 2016). 
Additionally, those who received only one dose also had detectable levels of HPV 
antibodies, but at lower concentrations (Sankaranarayanan et al., 2016). This could lead 
to the conclusion that those who had one dose would have a higher level of immunity to 
HPV as compared to natural immunity. Cervical samples from 2,649 participants were 
obtained to evaluate the efficacy of one, two, or three dose 4vHPV vaccine 
(Sankaranarayanan et al., 2016). Remarkably, the overall incidence of HPV strains 6, 11, 
16, and 18 detected in cervical samples were comparable for those participants who 
received one, two, or three doses of vaccine (Sankaranarayanan et al., 2016). The 
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researchers concluded that the two-dose vaccination schedule could have a significant 
impact on reducing global cervical cancer rates in low to middle income countries where 
adherence to the vaccine schedule is less successful than higher income countries and that 
more research needs to be done examining one-dose vaccine programs 
(Sankaranarayanan et al., 2016). 
HPV Vaccine Rates 
 Though evidence exists to support alternative dosing schedules and ACIP 
guidelines recommend the two-dose schedule for those ages 9-14, overall vaccine rates 
should be examined to identify if gaps in meeting the three-dose recommendation exist in 
other vaccine eligible populations (Iverson et al., 2016; Meites, Kempe, & Markowitz, 
2016; Sankaranarayanan et al., 2016). In a review of 21,875 participants of the 2015 
National Immunization Survey-Teen (NIS-Teen), data regarding HPV vaccination among 
teens both male and female ages 13-17 years was obtained (Reagan-Steiner, 2016).  A 
review of provider reported vaccine histories showed only 39.4% of those vaccinated had 
received three doses of HPV vaccine (Reagan-Steiner et al., 2016). Many participants 
initiated the series, 56.1%, but the percentage of those who continued with the series 
began to lag with dose two at 45.4%. (Reagan-Steiner et al., 2016). The researchers 
suggest that HPV vaccination rates remain low due to inconsistent recommendations by 
providers, lack of co-administration of HPV vaccine with other childhood immunizations, 
and misinterpretation of risk exposure and parental concerns (Reagan-Steiner et al., 
2016).  Even with the 2016 ACIP guideline changes recommending a two-dose vaccine 
series for those ages 9-14, the overall vaccination rate of only 45.4% for two doses in the 
NIS-Teen sample is far less than desirable. Though ACIP recommendations support two-
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doses for the young-adolescent subset, the guidelines still delineate a three-dose schedule 
for those ages 15-26 due to the body of research regarding two-dose immunogenicity and 
efficacy being conducted on those participants under the age of fifteen (Iverson et al., 
2016; Meites, Kempe, & Markowitz, 2016; Sankaranarayanan et al., 2016).  
 As children progress into adulthood, overall HPV vaccination rates decline.  In a 
review of the 2014 National Health Interview Survey (NHIS), with a sample of 36,324 
participants ages 19 years or greater, data findings showed that only 40.2% of women 
ages 19-26 and 8.2% of men ages 19-26 reported receiving greater than or equal to one 
dose of HPV vaccine (Williams et al., 2016). Some noted barriers to vaccination include 
status of health insurance coverage and accessibility to a consistent healthcare provider 
(Williams et al., 2016). With the rates of adolescent and young adult vaccinations 
remaining low, the population continues to be at risk for HPV-associated diseases 
including dysplastic tissue changes and cancer.  ACIP dosing guidelines now include 
“catch-up” dosing schedules for older adolescents and young adults ages 13-26, and this 
could greatly impact the overall numbers of adults who have been vaccinated (Meites, 
Kempe, & Markowitz, 2016; Williams et al., 2016). Federal programs such as the 
Vaccines for Children program that offers no-cost vaccination to those under the age of 
19 who qualify for Medicaid, are uninsured, or underinsured, may support increased 
vaccination rates (CDC, 2016; Williams et al., 2016). However, health care providers 
should pursue alternate opportunities to vaccinate young adults, especially women who 
are at great risk for developing cervical cancer from HPV infection (Williams et al., 
2016). 
Postpartum HPV Vaccination 
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Pregnancy is a period of time when many women have increased access to 
healthcare providers who can educate about HPV and HPV vaccination (Kilfoyle, 
Rahangdale, & Dusetzina, 2016). Though HPV vaccine is not recommended in 
pregnancy, this access provides an opportunity for health care providers to discuss the 
benefits of postpartum HPV vaccination and to educate patients concerning the risk of 
HPV.  
The potential of postpartum HPV vaccination programs is dependent upon the 
feasibility and acceptability of postpartum vaccination programs. In a study of 150 
postpartum women ages 18-26, researchers examined participants’ overall acceptance of 
quadrivalent HPV vaccine in the postpartum period and their subsequent compliance with 
the three-dose series completion (Wright et al., 2012). Study participants were 
approached on day one or two of postpartum hospitalization. If agreeable to vaccination, 
participants received free-of-charge HPV vaccine while inpatient.  Dose two was 
administered at the postpartum visit, with the third-series dose given during a subsequent 
follow-up appointment (Wright et al., 2012). Adherence rates through dose three were 
studied to determine if receiving the vaccine during the postpartum period was conducive 
to participants completing the series. Findings showed that 4.7% of participants did not 
receive any vaccines, 41.3% received one dose, 23.3% received two doses, and 30.7% 
received all three doses (Wright et al., 2012). Additionally, patient satisfaction with 
receiving the vaccine while postpartum was surveyed, with 97.2% of participants 
reporting overall satisfaction with vaccination (Wright et al., 2012).  
In a similar study of 500 pregnant women under the age of 26, researchers 
examined the likelihood of HPV vaccine acceptance in the postpartum period if the 
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vaccination was offered free-of-charge (Berenson et al., 2014).  The researchers also 
investigated barriers related to why women were not previously vaccinated (Berenson et 
al., 2014).  Of those participants who reported that they were not previously vaccinated or 
who had not completed the series, 83% were willing to receive free-of-charge vaccine 
during the postpartum period (Berenson et al., 2014). Barriers to HPV vaccine series 
initiation or completion were reported as lack of prior knowledge about HPV, HPV 
vaccination, and safety (Berenson et al., 2014). Providing education to patients during the 
prenatal visit about the risk and effects of HPV, vaccination efficacy and overall safety, 
and administration of vaccine during the inpatient hospital stay could be an opportunity 
for providers to increase vaccination rates (Berenson, et al., 2014). 
Despite evidence that patients are willing to accept vaccination, research suggests 
that postpartum vaccine initiation and series completion has been low. In a review of 
48,001 health records of privately-insured female patients ages 18-26, covering the years 
between 2006 and 2012, 861 women received an HPV vaccine, with 337 completing the 
three-dose series within one year postpartum (Kilfoyle, Rahangdale, & Dusetzina, 2016). 
Research findings indicate that fewer than two percent of eligible patients received the 
vaccine and that opportunities exist for prenatal care providers to increase patient 
awareness of HPV-associated disease and recommend vaccination in the postpartum 
period (Kilfoyle, Rahangdale, & Dusetzina, 2016). 
The evidence of high incidence and prevalence of HPV virus is irrefutable, with 
one in four American’s being infected with the virus (CDC, 2017).  Despite evidence that 
the immunogenic response and vaccine efficacy of HPV vaccine are positive, overall 
vaccine rates remain low. Regardless of recommendations by ACIP, vaccination rates 
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that show only 45.4% of the targeted population have received the HPV vaccination are 
unsatisfactory (Reagan-Steiner et al., 2016). Research suggests that alternative 
opportunities to vaccinate at-risk populations should be explored (Berenson et al., 2016; 
Kilfoyle, Rahangdale, & Dusetzina, 2016).  With pregnancy, many women seek health 
promoting behaviors. HPV education and vaccination should be incorporated in the 
prenatal care delivery model so that patients are aware of their risks and opportunities for 
primary prevention (Berenson et al., 2016; Kilfoyle, Rahangdale, & Dusetzina, 2016).   
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Theoretical Framework 
The Program Logic Model (PLM) was chosen as the theoretical framework to 
guide this project. Program evaluation encompasses more than the assessment of 
outcomes. To determine the effectiveness of a projected outcome, one must take 
methodical steps to develop activities that bring about positive transformational change 
(W. K. Kellogg Foundation, 1998). The Program Logic Model can guide both program 
development and program evaluation (W. K. Kellogg Foundation, 1998). This model 
utilizes a five-step approach of resource identification, activities or resource utilization, 
outputs or results of planned activities, outcomes or accomplishments, and impact or 
overall benefit to the stakeholders (W. K. Kellogg Foundation, 1998).  The framework of 
the PLM is presented in Figure 1 below (University of Kansas, 2018). 
 
Figure 1. Program Logic Model Framework (University of Kansas, 2018). 
Identification of the gap in HPV vaccination rates for young women ages 19-26 
years is the beginning of the process for application of the PLM. Following the cause and 
effect principles of logic, one can determine if the HPV pilot vaccine program has 
accomplished the objective of increasing HPV vaccine uptake and completion rates in the 
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targeted population. The interconnectedness of planning and implementation to the 
outcome should remain visible throughout the evaluation of the program’s effectiveness.  
 With each step in the logic model comes some aspect of change, making the 
theory of change the theoretical underpinning of the PLM (W. K. Kellogg Foundation, 
1998). Within change theory, old practices are replaced with newer more productive 
processes (W. K. Kellogg Foundation, 1998). Regarding the HPV vaccine program at 
Women and Infants Hospital, these changes include obtaining state-supplied HPV 
vaccine for patients ages 19-26 and introducing clinical practice changes with outpatient 
providers to identify HPV vaccine eligibility. Additional, process changes include 
inpatient nurses administering HPV vaccine to inpatient postpartum patients. Finally, 
adjustments to the postpartum care delivery model with the administration of HPV 
vaccine at the postpartum visit will be necessary. Further changes include revisions to 
previous workflow practices that will lead to an increased rate of overall HPV vaccine 
administration to Obstetrics and Gynecology Care Center patients. Both change and logic 
are not always linear, but should remain commonsense and be examined for their causal 
relationship (W. K. Kellogg Foundation, 1998). 
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Method 
Purpose 
 The purpose of this evaluation was to assess the effectiveness of a newly 
developed pilot program for women ages 19-26 that incorporates assessment of HPV 
vaccine eligibility during the prenatal period to increase uptake and completion of HPV 
vaccine during the postpartum period. 
Description of the Program 
Women and Infants Hospital is a tertiary care center in an urban area in the 
northeastern US which performs approximately 8,500 deliveries per year and is the ninth 
largest obstetrical service in the country (Care New England, 2017). The Obstetrics and 
Gynecology Care Center serves a large ethnically and culturally-diverse patient 
population, many of whom are underinsured and medically underserved.  
Prior to the implementation of the pilot perinatal HPV vaccination program, 
assessment of the HPV vaccination status of Obstetrics and Gynecology Care Center 
patients was conducted at gynecologic office visits only. The implementation of this 
assessment prenatally, as well as the administration of the HPV vaccine during the 
postpartum hospitalization at Women and Infants Hospital is newly established practice 
that began in March 2017.  The primary eligibility criterion for this pilot program is that 
patients must have received prenatal care at the Obstetrics and Gynecology Care Center. 
 The aim of the perinatal HPV vaccine program is to increase HPV vaccination 
uptake through the complete three-dose series for Obstetrics and Gynecology Care Center 
patients, ages 19-26. Patients ages 19-26 who receive prenatal care at the Women and 
Infants Hospital Obstetrics and Gynecology Care Center are assessed for HPV vaccine 
eligibility by the nurse practitioner or resident during a third-trimester office visit. 
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Criteria for vaccine eligibility include a history of no previous HPV vaccination or a 
history of incomplete vaccine series. Additionally, because the vaccine dispensed by the 
hospital pharmacy is state-supplied vaccine (SSV) for adults over the age of 19, patients 
must be Rhode Island residents or non-Rhode Island residents who are not insured by a 
Rhode Island employer to receive vaccination (Rhode Island Department of Health, 
2017). Contraindications include an allergy to yeast or a previous allergic reaction to 
HPV vaccine.   
The provider documents vaccine eligibility in the electronic medical record 
(EMR) of those patients who have not begun or completed the HPV vaccine series, do 
not have contraindications, and who agree to accept the vaccine during the postpartum 
period. The provider documents ineligibility in the EMR of those patients who have 
completed the series, have an identified contraindication, or decline.  
The outpatient medical record contains a text box for the provider to include a yes 
or no answer for vaccine eligibility. The EMR template does not require the provider to 
include a rationale for vaccination eligibility or ineligibility. However, a comment section 
has been established for the provider if they choose to document this information. The 
outpatient EHR template containing the HPV vaccine text box is interfaced into the 
inpatient EHR prior to the patient’s estimated due date. In addition, all residents have 
access to both the outpatient and inpatient EHRs so that they may access the required 
prenatal assessments upon inpatient admission from labor and delivery. 
The inpatient EMR templates for post-cesarean and post-vaginal delivery care 
includes an HPV order sentence that the provider chooses, post-delivery, for those 
patients who were pre-determined to be vaccine eligible during the prenatal period. The 
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electronic order then populates the medication administration record with the HPV 
vaccine order for the nurse caring for the patient during the postpartum hospital stay. 
Residents and nurse practitioners who provide care at the Obstetrics and Gynecology 
Care Center received education during resident education sessions and Grand Rounds 
about the new process of screening patients during the prenatal period. Additionally, 
residents received further training about ordering vaccine during the inpatient period as 
they are the providers that deliver obstetric services to inpatient Obstetrics and 
Gynecology Care Center patients.  
In addition to resident and nurse practitioner education, inpatient nurses on all 
units that provide postpartum care received education about HPV, HPV vaccination, and 
the new process for administering vaccine during the postpartum period. This education 
was in the form of a computer-based learning (CBL) module. Inpatient nurse managers 
and the mother-baby nurse educator were instrumental in encouraging CBL completion 
resulting in an 89% completion rate for assigned nursing staff. 
 One dose of the three dose HPV series is administered during the inpatient 
postpartum period, an additional dose in the series is administered at the outpatient 
postpartum appointment if warranted, and the final dose, if needed to complete the 
vaccine series, is administered at a follow-up outpatient nurse visit six months after dose 
one of the series or at a minimum of twelve weeks from dose two in the series. Each 
Obstetrics and Gynecology Care Center patient receives a letter reminding them to 
schedule their postpartum visit and robocalls are placed to patients 48 and 24 hours prior 
to their appointment as a reminder of their follow-up visit. Prior to vaccine 
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administration, vaccine information sheets are provided to each patient with each dose, as 
required by federal law.  
Administration of SSV during the inpatient hospitalization and postpartum visit 
does not result in an increased cost to the patient, as SSV is free of charge to eligible 
patients, and the administration fee is included in the maternity insurance coverage. 
However, if a lapse in insurance coverage occurs after the postpartum period, the SSV 
will remain without cost to patients, though the possibility of a negligible administration 
charge for the vaccine at the nurse follow-up visit may be realized. 
Research Questions 
The research questions for this program evaluation were: 
1. How many patients ages 19-26 received a dose of HPV vaccine after 
delivery while an inpatient at Women and Infants Hospital during the 
period of March 1, 2017 through December 31, 2017? 
2. How many patients ages 19-26 received a dose of HPV vaccine during the 
postpartum period while an outpatient at the Obstetrics and Gynecology 
Care Center during the period of March 1, 2017 through December 31, 
2017? 
3. How many patients ages 19-26 who received an inpatient HPV vaccine 
dose and a postpartum outpatient HPV vaccine dose also received an 
outpatient dose after the postpartum period during the period of March 1, 
2017 through December 31, 2017? 
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4. What percentage of HPV vaccines administered were given according to 
ACIP guidelines during the period of March 1, 2017 through December 
31, 2017? 
5. How many total HPV vaccinations were administered to Obstetrics and 
Gynecology Care Center patients ages 19-26 between June 1, 2016 
through February 28, 2017 prior to program implementation? 
6. How many total HPV vaccinations were administered to Obstetrics and 
Gynecology Care Center patients ages 19-26 between March 1, 2017 
through December 31, 2017? 
7. What is the number of Obstetrics and Gynecology Care Center patients 
ages 19-26 in the ten-months pre-program implementation? 
8. What is the number of Obstetrics and Gynecology Care Center patients 
ages 19-26 in the ten-months post-program implementation? 
Design 
 A retrospective chart review examining pre-program implementation and post-
program implementation of HPV vaccine data during June 1, 2016 through December 31, 
2017 was conducted. To answer the research questions, data on the number of inpatients 
who received HPV vaccine between March 1, 2017 through December 31, 2017 
including medical record number (MRN), date of birth, and date of vaccine 
administration was requested. Outpatient data, including MRN, date of birth, and date of 
vaccine administration, was requested on patients who had also received an inpatient 
HPV dose during the timeframe of March 1, 2017-December 31, 2017.  
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The number of Obstetrics and Gynecology Care Center patients ages 19-26 from 
June 1, 2016 through February 28, 2017 and March 1, 2017 through December 31, 2017 
was obtained. Also, the number of HPV vaccines given to all patients ages 19-26 at the 
Obstetrics and Gynecology Care Center from June 1, 2016 through February 28, 2017 
and March 1, 2017 through December 31, 2017 was tracked. 
Sample 
 The sample consisted of perinatal patients ages 19-26 who received prenatal care 
at the Women and Infants Hospital Obstetrics and Gynecology Care Center, were 
hospitalized postpartum at Women and Infants Hospital, and agreed to receive 
postpartum HPV vaccination. 
Sites 
 Women and Infants Hospital in Providence, Rhode Island and the outpatient 
Women and Infants Hospital Obstetrics and Gynecology Care Center in Providence, 
Rhode Island were the locations of the study.  
Procedures 
  A proposal for evaluating the Women and Infants Hospital Obstetrics and 
Gynecology Care Center perinatal vaccination pilot program was approved by both the 
Rhode Island College and the Women and Infants Hospital Institutional Review Boards 
(IRB). The IRB approval documents are available in Appendices A and B. Collaboration 
with the Care New England (CNE) Health System pharmacy informatics department and 
the Obstetrics and Gynecology Care Center Senior Division Manager was necessary for 
obtaining clinical data. Data on patients ages 19-26 focused on the time frames of June 1, 
2016 through February 28, 2017 and March 1, 2017 through December 31, 2107 and  
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included: the number of patients who received care at the Obstetrics and Gynecology 
Care Center; the number of HPV vaccines administered to Obstetrics and Gynecology 
Care Center patients; the number of vaccines administered to individual patients while 
inpatient at Women and Infants Hospital;  and the number of vaccines administered to 
individual patients while outpatient at the Obstetrics and Gynecology Care Center. Data 
collected from the perinatal vaccination pilot program was performed retrospectively. 
Patient identifiers associated with the data collection including MRN and dates of birth 
were electronically accessed and stored through the secured CNE data server to protect 
patient identity. 
 The request to the CNE pharmacy informatics department specifically included: 
1. Medical record number, date of birth, and date of injection for each 
patient, ages 19-26, who received a dose of HPV vaccine after delivery 
while an inpatient at Women and Infants Hospital between March 1, 2017 
through December 31, 2017. 
2. Medical record number, date of birth, and date of injection for each patient 
ages 19-26 who received a dose of HPV vaccine during the postpartum 
period while an outpatient at the Obstetrics and Gynecology Care Center 
between March 1, 2017 through December 31, 2017. 
3. Medical record number, date of birth, and date of injection for each patient 
ages 19-26 who received an inpatient HPV vaccine dose, a postpartum 
outpatient HPV vaccine dose, and also received an outpatient dose after 
the postpartum period; between March 1, 2017 through December 31, 
2017. 
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4. Number of total HPV vaccinations were administered to Obstetrics and 
Gynecology Care Center patients ages 19-26 between June 1, 2016 
through February 28, 2017 prior to program implementation, 
5. Number of total HPV vaccinations were administered to Obstetrics and 
Gynecology Care Center patients ages 19-26 between March 1, 2017 
through December 31, 2017. 
Chart review data from the CNE pharmacy informatics department was requested in 
report form including MRN, date of birth, and date of vaccine administration for all 
patients who received an inpatient dose of HPV vaccine. Additionally, outpatient data 
was requested on patients who received an inpatient dose including MRN, date of birth, 
and date of vaccine administration. Once patients were correlated to doses by MRN, the 
MRN data was electronically deleted and patients were assigned a number for 
identification to maintain anonymity.  
The data request to the Obstetrics and Gynecology Care Center Senior Division 
Manager included:  
1. Total number of Obstetrics and Gynecology Care Center patients ages 19-
26 in the ten-months pre-program implementation. 
2. Total number of Obstetrics and Gynecology Care Center patients ages 19-
26 in the ten-months post-program implementation. 
The chart review data was requested in report form as a total volume, again maintaining 
anonymity.  
As comparative data for pre-program inpatient HPV vaccination did not exist, a 
comparison of the number of HPV vaccines given from the Obstetrics and Gynecology 
  26 
 
Care Center in the 10 months pre-program implementation to the 10 months post-
program implementation was used to assess if the program was effective at increasing 
uptake and completion of HPV vaccine during the postpartum period. Through a chart 
review, postpartum patients age 19-26 were identified and specific areas of focus were 
examined. These included: 1). Was an HPV dose administered to vaccine eligible 
individuals during the inpatient period? 2). Was an additional dose administered at an 
ambulatory postpartum visit? and 3) Was a subsequent dose given at an ambulatory visit 
if warranted? 
Data Analysis 
Analysis of the data was performed using MRN’s to correlate patients to doses.  
In addition, dates of birth allowed for examination of trends in vaccination by age. Date 
of injection was analyzed to determine if doses were administered at appropriate 
intervals. Frequencies and percentages in relation to numbers of patients and HPV doses 
were calculated. 
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Results 
A total of 30 postpartum Obstetrics and Gynecology Care Center patients 
received a dose of HPV vaccine while inpatient at Women and Infants Hospital between 
March 1, 2017 and December 31, 2017. Prior to the implementation of the program in 
March 2017 no patients received HPV vaccine while inpatient at Women and Infants 
Hospital.  Table 1 shows the distribution by patient age with a mean age of 22.48 years.  
Table 1: Inpatient HPV Vaccines 3.1.17-12.31.17 by patient age 
 
Of the 30 patients who received an inpatient dose, six patients received a dose at 
their outpatient postpartum visit; and two patients received a third-dose at a subsequent 
outpatient visit. ACIP guidelines call for minimum intervals between HPV doses: four 
weeks between dose one and two, twelve weeks between dose two and three, and a 
minimum of five months from dose one to three (CDC, 2017). Table 2 shows the vaccine 
intervals for the selected patients who received doses following inpatient dosing. One 
patient, identified as patient 4, received a 4th dose of HPV vaccine 13.4 weeks after 
completing the 3-dose series.   
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Table 2: Vaccine Intervals, By Patient, Following Inpatient Dosing 
Vaccine Intervals, By Patient, Following Inpatient Dosing 
Patient Interval from Inpatient dose 
(weeks/days) 
Interval from Postpartum 
dose (weeks/days) 
1 5.6   
2 7.6  
3 5.3 22.6 
4 5 17.4 
5 6.1  
6 7  
  
 During the period from June 1, 2016 through February 28, 2017, 1918 patients 
ages 19 through 26 received care at the Obstetrics and Gynecology Care Center. During 
the same period, seventy HPV vaccines were administered to this patient subset, 
representing 4% of the patient population. Comparatively, during the period from March 
1, 2017 through December 31, 2017, 877 patients ages 19 through 26 received care at the 
Obstetrics and Gynecology Care Center. HPV vaccine given to this patient group totaled 
155 doses, representing 18% of the patient population and demonstrating an increase of 
14% following initiation of the program. Table 3 shows the percentages of HPV vaccine 
given to the targeted age group pre-program implementation and post-program 
implementation.  
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Table 3: Percentage of HPV Vaccine Given Pre- and Post-Program Implementation 
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Summary and Conclusions 
Summary 
 The purpose of this evaluation was to assess the effectiveness of a newly 
developed pilot program for women ages 19-26 that incorporates assessment of HPV 
vaccine eligibility during the prenatal period to increase uptake and completion of HPV 
vaccine during the postpartum period. A retrospective chart review examining pre-
program implementation and post-program implementation HPV vaccine data during 
June 1, 2016 through December 31, 2017 was conducted. The sample consisted of 
perinatal patients’ ages 19-26 who received prenatal care at the Women and Infants 
Hospital Obstetrics and Gynecology Care Center, were hospitalized postpartum at 
Women and Infants Hospital, and agreed to receive postpartum HPV vaccination. 
 A proposal for evaluating the Women and Infants Hospital Obstetrics and 
Gynecology Care Center perinatal vaccination pilot program was approved by both the 
Rhode Island College and the Women and Infants Hospital IRB. Chart review data was 
analyzed for all patients who received an inpatient dose of HPV vaccine. Additionally, 
outpatient data was requested on patients who received an inpatient dose. As comparative 
data for pre-program inpatient HPV vaccination did not exist, comparing the number of 
HPV vaccines given from the Obstetrics and Gynecology Care Center in the 10 months 
pre-program implementation to the 10 months post-program implementation was used to 
evaluate if the program was effective at increasing uptake and completion of HPV 
vaccine during the postpartum period. 
 The results of the chart review showed 30 patients who received an inpatient dose 
of HPV vaccine. Of these patients, six received a dose at their outpatient postpartum visit, 
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and two of these patients received a subsequent dose to complete the series. Of note, the 
EMR where vaccine eligibility is documented does not include any fields indicating if the 
patient was eligible for vaccination due to being unvaccinated or if the patient had not 
previously completed the vaccine series. This makes determining which number vaccine 
in the series was given impossible except for the two patients who received three doses.  
 Vaccine timing is an important factor with HPV vaccine series. ACIP guidelines 
call for minimum intervals between HPV doses: four weeks between dose one and two, 
twelve weeks between dose two and three, and a minimum of five months from dose one 
to three (CDC, 2017). Chart review data for the six patients who received doses at their 
outpatient postpartum visit showed all received their dose within the appropriate interval 
with an average date of receipt being 6.1 weeks from their inpatient dose. Data for the 
two patients who received a third-dose in the series also met the ACIP minimum dosing 
interval for dose three. However, one patient who had received all three doses in the 
appropriate dosing interval received a fourth dose. The use of separate EMR systems for 
inpatient and outpatient documentation may have caused this discrepancy to occur.  
Limitations 
 An examination of the number of HPV doses given to Obstetrics and Gynecology 
Care Center patients ages 19-26 given in the 10-months pre-program implementation and 
the 10-months post-program implementation showed an overall increase of 14.02%. It is 
difficult to determine if the vaccination increase is a result of the concurrent introduction 
of free of charge, to eligible patients, state supplied HPV vaccine or due to the process 
changes implemented to include screening of prenatal patients for vaccine eligibility. In 
addition, data examined was for doses of HPV vaccine given to all Obstetrics and 
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Gynecology Care Center patients ages 19-26 pre and post program and did not 
specifically analyze data for pregnant patients alone. 
Conclusion  
 In the evaluation of the effectiveness of the pilot program for women ages 19-26 
that incorporated assessment of HPV vaccine eligibility during the prenatal period to 
increase uptake and completion of HPV vaccine during the postpartum period, several 
discoveries occurred. With the determination of vaccine eligibility, prenatally patients do 
express interest in being vaccinated in the inpatient setting. Without data on the overall 
number of pregnant patients who received care at the Obstetrics and Gynecology Care 
Center during the two-examined time frames, it is not possible to determine the 
percentage of pregnant patients who received the vaccine as inpatients or during their 
outpatient visits. However, the data is encouraging in that pre-program HPV vaccination 
was not occurring in the inpatient setting and with the introduction of this program, 30 
eligible patients did receive vaccination. Prior research has shown that HPV titers 
increase even with one vaccine though at lower levels then the complete vaccine series 
(Sankaranarayanan et al., 2016). The conclusion that may be reached is that even one 
dose of HPV vaccine could result in a higher level of immunity than natural immunity 
alone, thereby decreasing the potential of HPV infection and resultant morbidity and 
mortality from related cancers.  
Looking beyond the examined patient population of women ages 19-26, further 
research on strain-specific HPV infection rates in women may determine if vaccination 
programs that target all eligible patients results in a decrease in HPV related cancers in 
the future. In October, 2018, the Federal Drug Administration approved the use of 
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Gardasil 9 for both men and women ages 27 through 45 years old for the prevention of 
vaccine specific HPV-associated cancers, dysplasias, and genital condyloma (U. S. 
DHHS, 2018).  Notably, though expanded HPV vaccination has received FDA approval, 
insurance carriers have yet to reach a universal determination on vaccine cost or coverage 
to the direct consumer.   
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Recommendations and Implications for Advanced Nursing Practice 
In the United States, seventy-nine million Americans, or one in four, are infected 
with HPV (CDC, 2017). By targeting HPV strains that are oncogenic and related to 
genital condyloma, HPV vaccine could be revolutionary in combating the most prevalent 
sexually transmitted infection worldwide. Though vaccine efficacy is greatest when 
introduced prior to sexual debut, evidence supports that HPV vaccination for eligible 
patients through the age of 26 may be beneficial in offering protection against HPV 
strains not previously acquired and could significantly impact the rates of HPV-
associated cancers in women (Serrano et al., 2012).  
As the prevalence of HPV infection is widespread, on a macro-level, our entire 
global society becomes stakeholders in the vaccination debate which has significant 
implications for clinical practice. With a narrower focus, those greatly impacted are the 
children of today who are at-risk for HPV infection due to sexual exposure in the future. 
Additional stakeholders, on both a macro and micro-level, include individual vaccine 
recipients, parents, healthcare providers, healthcare systems, and policy makers. 
Providing evidence-based education to stakeholders, increasing vaccine accessibility to 
all eligible populations including adults through age 26, and seeking alternate options for 
HPV vaccination beyond the primary care providers office is crucial.  
With most HPV vaccine programs targeting adolescents, opportunities exist to 
examine those that support and promote the vaccination of other eligible populations. 
Increasing human papillomavirus (HPV) vaccination rates can be considered a priority 
based on the major drivers of public health quality. Those drivers include population-
centered services that prevent and control disease (Honoré et al., 2011). In addition, 
public health quality programs must fundamentally be proactive, health-promoting, and 
  35 
 
risk-reducing in that they aim to mitigate current and emerging disease, increase positive 
outcomes, and prevent illness or negative results (U.S. DHHS, 2008). HPV vaccination 
programs align with the aims in that vaccination before sexual debut is proactive in 
preventing HPV, health-promoting as it targets reduction of HPV in society, and risk-
reducing in its ability to prevent HPV-associated sequalae. 
Public policy surrounding HPV vaccination has and continues to be a 
controversial topic . With many states enacting legislation to support, mandate, and 
provide access to HPV vaccine. Many others have fought to minimize governmental 
involvement in HPV vaccination or expand legislation that allows for parents to “opt out” 
for moral or philosophical reasons. It is important that policies that require HPV 
vaccination expand beyond our state and our nation and expand to our global community. 
HPV-associated cancers are preventable through vaccination. Not only should children 
on the state level be afforded the opportunity to live without HPV-associated disease, but 
this same opportunity should be supported, promoted, and encouraged by national and 
worldwide policy makers. 
Development and promotion of HPV vaccination programs is a core goal of 
public health nursing practice as nurses promote and protect the health of populations 
(American Public Health Association, 2013). “Population-focused nursing integrates the 
tenets of public health with clinical care, thus contributing to improving the health of 
communities and population” (Storfjell, Winslow, & Saunders, 2017). Developing a 
program for HPV vaccination involves a variety of nursing interventions including: 
developing policy; making HPV vaccination standard practice and equitably available; 
advocating for and promoting HPV primary-prevention programs; and educating the 
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community at-large who are all significantly affected by the negative impact of HPV. 
Opponents of HPV vaccination have voiced their concern due to ethical, religious, moral, 
and political reasons. While proponents have supported the vaccine’s efficacy, economic 
savings, and societal impact in reducing overall HPV rates and the long-term sequelae 
associated with HPV infection.  
Further research is necessary to continue to reduce the prevalence of HPV in 
society and decrease the burden of disease associated with this preventable virus. As 
HPV vaccine is relatively young in comparison to many childhood immunizations new 
and emerging data on vaccine efficacy continues to lead to practice changes in HPV 
vaccination. This can be seen currently in the reduction of the vaccine series from three 
doses to two doses for certain populations under age 15. With expanded research, 
barriers, attitudes, and accessibility to HPV vaccination should be explored. Additionally, 
further research on 2-dose vaccine series for additional populations should be 
investigated. Nurses are poised to make a significant impact on women’s’ health as they 
seek innovative ways to introduce evidence-based research and practice to improve the 
health of the population.  
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- 1 - Generated on IRBNet 
DATE: February 28, 2018 
Project No. WIH 17-0108 
101 Dudley Street 
Providence, Rhode Island 02905 
401-274-1100 
womenandinfants.org 
LETTER OF APPROVAL 
PROJECT TITLE: [1133642-2] EVALUATION OF A PERINATAL HUMAN PAPILLOMAVIRUS 
VACCINATION PROGRAM 
TO: Lauren Thorngate 
FROM: Care New England - Women & Infants IRB (IRB00000746) 
SUBMISSION TYPE: Response/Follow-Up 
ACTION: APPROVED 
APPROVAL DATE: February 28, 2018 
EXPIRATION DATE: January 25, 2019 
EXPEDITED REVIEW: In accordance with 45 CFR 46.110(b)(1), Category 5 
Thank you for submitting the Response/Follow-Up materials for this project. The Care New England - 
Women & Infants IRB has APPROVED your submission. The IRB conducted a risk-benefit analysis, and 
determined the research falls into the category "Minimal Risk." This approval is based on an appropriate 
risk/benefit ratio and a project design wherein the risks have been minimized. All research must be 
conducted in accordance with this approved submission. 
The following items are acknowledged in this submission: 
• Care New England - Research Application - Care New England - Research Application (UPDATED: 
02/5/2018) 
• Other - Administrative Report Form (UPDATED: 02/16/2018) 
• Protocol - Retrospective Protocol track changes (UPDATED: 02/16/2018) 
• Protocol - Retrospective Protocol.clean copy (UPDATED: 02/16/2018) 
This submission has received Expedited Review based on applicable federal regulations. It is the 
responsibility of the principal investigator to ensure that the study is conducted as approved by the IRB. 
All protocol modifications/changes must be approved by the IRB before any changes are implemented 
except when necessary to eliminate immediate hazard to subjects. You are required by federal 
regulations and hospital policy to immediately report any unanticipated problems untoward effects or 
reactions, serious side effects and/or deaths of subjects involved and related to this project to the IRB. 
If written informed consent is required: the consent form(s) have been stamped and are available 
under Board Documents in IRBNet. Please review the consent form(s) to be sure they are correct and 
are stamped with IRB approval and expiration dates. The consent form(s) and other study documents 
included in this submission are to be used immediately for this study and void any previously issued 
documents, if applicable. 
IRB approval for this project expires on January 25, 2019. If you wish to continue your research after 
this date, you are required to submit a continuing review form 45 days prior to expiration of approval. 
Federal regulations do not allow for any grace period for renewal. 
- 2 - Generated on IRBNet 
Please provide a study closure report to the IRB when research is completed. The study closure 
submission form (SUBMISSION FORM: Continuing Review or Closure Report) as well as all other forms 
(e.g., amendment/modification, event reporting, etc.) are located in the Forms and Templates Library in 
IRBNet. 
NO RESEARCH DATA SHOULD EVER BE STORED ON A LAPTOP. This includes data from chart 
reviews, surveys, and all types of research. Obtaining consent and research authorization does not 
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remove the requirements and restrictions of the HIPAA security rule. For more information contact IRB 
Administration. 
This institution is in compliance with the ICH GCP as they correspond to the FDA/DHHS regulations. 
This document has been electronically signed in accordance with all applicable regulations, and a copy is 
retained within our records. 
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Appendix B 
 
The proposal for the project referenced below has been APPROVED by the Institutional 
Review Board (IRB). 
 
Project title: Evaluation of a Perinatal Human Papillomavirus Vaccination Program 
 
Approval #: 1718-1583 
Type of review: Expedited 
Proposal type: Original 
Principle Investigator: Byrd, Mary 
Fees received: 1. No fees -- RIC supervised or sponsored 
Funding status:  
 
Approval date:  3/14/2018 
Expiration date:  3/14/2019 
A request to renew this protocol must be received by 2/14/2019.   
 
Click here to access the protocol: 
https://ric.topazti.net/RIC/SL/Default.aspx?linkParms=NPqkQNfZcnVbDZabLuFdTg%3d%
3d 
Your responsibilities as the Principal Investigator on this project are as follows:  
 
1. You may implement only those materials and methods approved by the IRB.  Changes 
to the protocol topic or methods, including the elimination of previously-approved 
methods, require prior approval.   
 
2. If you are using signed consent materials, a PDF of the form(s) with the approval 
stamp will be uploaded to your protocol.  You must use this copy with participants.  
 
3. Unanticipated problems or adverse events must be reported within three (3) days of 
your knowledge of the event. 
 
4. If you wish to continue the project beyond the expiration date, you must complete 
and submit a progress/final report within 30-days prior to the expiration date. If approval 
to continue the project is not finalized by the expiration date, you must discontinue all 
work pertaining to this protocol and wait until approval is given before resuming data 
collection.  
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5. You must keep all research data and consent documents within your possession in a 
secured location for at least three (3) years after the completion of the study, including 
publications or presentations of any reports. 
 
Do not reply to this "RIC_Elements" email address because it will not be received by the 
IRB.  Send all correspondence to IRB@ric.edu.  
 
Best Regards,  
 
Cindy Padula, Ph.D. 
Professor 
Chair, IRB 
Rhode Island College 
IRB@ric.edu 
